A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
References within this Annual Report to “Tandem,” “we,” “our,” “us,” “management,” or the “Company” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries. Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology, specializing in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management. We serve nearly 500,000 people living with diabetes in more than 25 countries worldwide. Our strategy is to offer flexibility and choice in intelligent insulin delivery systems through an accessible portfolio of market-leading pumps, applications and insights. In support of this strategy, our Tandem pump platforms include t:slim X2 and Tandem Mobi (Mobi), both of which feature Control-IQ+ advanced hybrid closed-loop technology. Diabetes and the Insulin Therapy Management Market Diabetes is a chronic, life-threatening disease for which there is no known cure.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.0B | 1.0B | 940M | 748M | 801M | 703M |
| Net Income | -205M | -205M | -96M | -223M | -95M | 16M |
| EPS | $-3.04 | $-3.04 | $-1.47 | $-3.43 | $-1.47 | $0.24 |
| Free Cash Flow | -30M | -30M | 5.0M | -59M | 16M | 97M |
| ROIC | -29.1% | -39.5% | -16.4% | -33.7% | -13.2% | 21.3% |
| Gross Margin | 53.8% | 53.8% | 52.1% | 49.2% | 51.5% | 53.5% |
| Debt/Equity | 2.86 | 2.86 | 1.80 | 1.33 | 0.95 | 0.73 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -187M | -187M | -99M | -233M | -93M | 23M |
| Operating Margin | -18.5% | -18.5% | -10.5% | -31.2% | -11.6% | 3.2% |
| ROE | -131.9% | -97.9% | -33.3% | -59.1% | -21.7% | 3.9% |
| Shares Outstanding | 67M | 67M | 65M | 65M | 64M | 65M |
TANDEM DIABETES CARE INC passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 52.0%. At current prices, the estimated annualized return to fair value is +6.8%.
TANDEM DIABETES CARE INC (TNDM) has a 5-year average return on invested capital (ROIC) of -16.3%. This is below average and may indicate limited pricing power.
TANDEM DIABETES CARE INC (TNDM) has a market capitalization of $1.4B. It is classified as a small-cap stock.
TANDEM DIABETES CARE INC (TNDM) does not currently pay a regular dividend.
TANDEM DIABETES CARE INC (TNDM) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
TANDEM DIABETES CARE INC (TNDM) reported annual revenue of $1.0 billion in its most recent fiscal year, based on SEC EDGAR filings.
TANDEM DIABETES CARE INC (TNDM) has a net profit margin of -20.2%. The company is currently unprofitable.
TANDEM DIABETES CARE INC (TNDM) generated $-30 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
TANDEM DIABETES CARE INC (TNDM) has a debt-to-equity ratio of 2.86. This indicates higher leverage, which may increase financial risk.
TANDEM DIABETES CARE INC (TNDM) reported earnings per share (EPS) of $-3.04 in its most recent fiscal year.
TANDEM DIABETES CARE INC (TNDM) has a return on equity (ROE) of -97.9%. A negative ROE may indicate losses or negative equity.
TANDEM DIABETES CARE INC (TNDM) has a 5-year average gross margin of 52.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for TANDEM DIABETES CARE INC (TNDM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
TANDEM DIABETES CARE INC (TNDM) has a book value per share of $2.30, based on its most recent annual SEC filing.